Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda’s OTC Unit to Be Renamed Alinamin with New Chief from Blackstone
Takeda Consumer Healthcare (TCHC), Takeda Pharmaceutical’s to-be-offloaded Japanese OTC business unit, will be renamed Alinamin Pharmaceutical on March 31, bearing the name of its iconic vitamin brand. The name change will come in conjunction with its scheduled transfer to US…
To read the full story
Related Article
- Blackstone to Sell Alinamin to MBK Partners
July 4, 2024
- Alinamin Invites New President from Non-Pharma Sector
June 22, 2022
- Alinamin Aims for Growth via Retail Promotion, Full Entry into Asia: President
April 2, 2021
- Takeda Completes Divestment of Consumer Healthcare Unit to Blackstone
April 1, 2021
- Blackstone Setting Sights on IPO of Takeda Consumer Healthcare Within 5-10 Years
September 4, 2020
- Takeda to Offload Japan OTC Biz to Blackstone for 242 Billion Yen
August 24, 2020
BUSINESS
- Takara Bio to Transfer Cell Processing CDMO Biz to S-RACMO
July 22, 2026
- Takara Bio Voluntary Buyout Draws 148 Employees
July 22, 2026
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Rhythm Pharma Gears Up for First Japan Launch with 50-Strong Team
July 21, 2026
- Fujifilm Toyama Chemical Forms 1st Product-Dedicated Unit for Savyscus
July 21, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…